title: Efficacy and safety of oral fludarabine/cyclophosphamide regimen in previously treated indolent lymphomas.
authors.forename: Vittorio
authors.initials: V
authors.lastname: Stefoni
authors.forename: Lapo
authors.initials: L
authors.lastname: Alinari
authors.forename: Gerardo
authors.initials: G
authors.lastname: Musuraca
authors.forename: Monica
authors.initials: M
authors.lastname: Tani
authors.forename: Enrica
authors.initials: E
authors.lastname: Marchi
authors.forename: Annalisa
authors.initials: A
authors.lastname: Gabriele
authors.forename: Mariapaola
authors.initials: M
authors.lastname: Fina
authors.forename: Stefano
authors.initials: S
authors.lastname: Pileri
authors.forename: Michele
authors.initials: M
authors.lastname: Baccarani
authors.forename: Pier Luigi
authors.initials: PL
authors.lastname: Zinzani
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D013997:Time Factors; D016896:Treatment Outcome; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine